TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07287033: A Randomized, Quadruple-blinded, Placebo-controlled, Single-ascending and Multiple Dose Study to Evaluate the Safety, Local Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Exploratory Clinical Activity of MY006 in Healthy Volunteers and Adolescent and Adult Patients With Peanut Allergy

Sponsor: Mabylon AG · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 48 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$774,180

Rescue Site Savings

+$516,120

Unlock Full NCT07287033 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07287033 Rescue Dossier →